NCT03008109

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Zaiwen Fan · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

EGFR Tyrosine-Kinase Inhibitor monotherapy is widely used in treatment of patients with EGFR mutation-positive Non-small cell lung cancer(NSCLC), In despite of the benefit of PFS （progression-free survival） , the OS （ overall survival） is limited extended. This study is aim to observe the safety and efficacy of the combination of an anti-angiogenic drug recombinant human-endostatin with EGFR TKI ,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

Conditions

• Advanced Cancer
• Lung Cancer, Nonsmall Cell

Interventions

Type	Name	Description
DRUG	EGFR-TK Inhibitor

Timeline

• Start date: 2017-02-01
• Primary completion: 2017-11-01
• Completion: 2018-11-01
• First posted: 2017-01-02
• Last updated: 2017-01-04